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CASE REPORTS
There are many reports describing the develop-
ment of abdominal aortic aneurysms (AAAs) after
renal and cardiac transplantation.1-6 The incidence
of AAAs seems to be high in patients who undergo
heart transplantation, particularly when the indica-
tion for the transplantation is end-stage coronary
artery disease.1,2 These aneurysms are also noted to
enlarge at more rapid rates than seen in the non-
transplantation population.4 We recently treated a
young patient in whom an AAA developed 10 years
after the lung transplantation. In the 18 months
before repair, the aneurysm also expanded quite
rapidly. In common with cardiac transplant recipi-
ents, our patient underwent immunosuppression
therapy with cyclosporine, azathioprine, and pred-
nisone. We will examine the possibility that these
medications have a role to play in the development
and expansion of AAAs.
CASE REPORT
The patient was a 39-year-old man with a history of
cystic fibrosis for which he underwent a double lung trans-
plantation in 1988. During a work-up for unexplained
weight loss 18 months before admission, a 4-cm AAA was
noted on the computed axial tomography scan. An ultra-
sound scan performed just 2 weeks before admission
showed that the AAA was now 5 cm in diameter. At that
time, the patient was asymptomatic, and an elective
aneurysm repair was being planned. On the day of admis-
sion, the patient was taken to the emergency department
with acute onset of severe epigastric abdominal pain with
radiation to the back.
His medical history includes renal failure as the result
of cyclosporine toxicity for which he was undergoing
hemodialysis. He also had a cardiomyopathy with severe
mitral valve regurgitation and an ejection fraction of 25%.
The patient was doing well from a pulmonary point of
view. He was not smoking nor was he known to be hyper-
lipidemic. The patient’s condition had been maintained
with prednisone, cyclosporine, and azathioprine since the
transplantation. Other medications included digoxin,
lisinopril (Prinivil), and metoprolol.
Physical examination revealed an anxious gentleman in
a mild amount of distress. His pulse was 81 and he was not
hypotensive. His abdominal examination showed a midline
scar from a previous laparotomy and a pulsatile aortic
aneurysm that was now tender. He had easily palpable
peripheral pulses. Laboratory analysis showed a hemoglobin
level of 146 g/L and a creatinine level of 555 µmol/L, in
keeping with his known renal failure. A computed axial
tomography scan of the abdomen with contrast showed a 5-
cm infrarenal AAA with no evidence of rupture (Fig 1). The
scan also showed a 2.1-cm splenic artery aneurysm in the
proximal third of the artery (Fig 2).
An emergency operation was performed for the
patient’s symptomatic AAA. A midline laparotomy was
performed, and multiple adhesions from previous surgical
procedures were taken down. There was no evidence of
rupture or leak from the aneurysm, which was 5 cm. No
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unusual features about the aneurysm itself were noted; it
had the appearance of a typical atherosclerotic aneurysm.
The proximal left iliac was aneurysmal as well. The
aneurysm was repaired in a standard fashion with a bifur-
cated 14 × 7-mm graft from the infrarenal aorta to the
common iliacs on both sides. The splenic artery aneurysm
was ligated both proximally and distally without removal
of the spleen. The patient was given stress-dose steroids,
and immunosuppression was continued after the opera-
tion through the nasogastric tube. The patient underwent
extubation immediately after the operation and received
an epidural infusion for pain control. There were no major
complications after the operation, and he was discharged
on the postoperative day 6. He is doing well now, 5
months after the operation. A duplex scan performed 3
months after the operation showed flow in the distal
splenic artery only, and the aneurysm was not visualized.
DISCUSSION
There have been a number of reports recently on
the occurrence of AAAs in cardiac transplant recipi-
ents.1-4 The aneurysms are morphologically the
same as in the nontransplantation population and
distinct from the mycotic thoracic aortic aneurysms
that occur in the setting of mediastinal sepsis after
the operation. The development of AAAs in patients
undergoing cardiac transplantation is an important
problem, and patients undergoing transplantation
for ischemic cardiomyopathy seem to be at particu-
lar risk.1,3,4 Pitrowski et al2 found that 4.3% of all
the cardiac transplant recipients they studied had
AAAs, and in the subgroup of patients who had
ischemic cardiomyopathy as the indication for trans-
plantation, the incidence rose to 10.5%. The devel-
opment of AAAs in cardiac transplant recipients may
be a manifestation of their tendency to experience
the development of peripheral vascular disease in
general.5 However, these aneurysms do not occur
exclusively in the group who undergoes transplanta-
tion for ischemic cardiomyopathy, and other factors
may be involved. There are many reports of AAAs
after kidney transplantation, but the precise inci-
dence of this problem in any single group of trans-
plant recipients is not documented because most
reports tend to concentrate on the technical aspects
of the procedure.6
A very important and uniformly observed feature
about AAAs in the cardiac transplantation popula-
tion is that they enlarge rapidly.1,2,4 Ammori et al4
reviewed the literature and found a mean aneurysm
growth rate of 1.10 cm/year in AAAs that were
diagnosed after cardiac transplantation. In contrast,
a 10-mm growth of an AAA in 1 year is expected in
less than 0.3% of aneurysms discovered in the popu-
lation at large.7 Pitrowski et al2 studied 98 cardiac
transplant recipients with routine ultrasound scans
JOURNAL OF VASCULAR SURGERY
586 Lokanathan and Taylor March 2000
Fig 1. Nonenhanced CT scan shows a 5-cm infrarenal AAA without evidence of leak or rupture.
before and after cardiac transplantation. They found
five AAAs in this group. Four of the five AAAs were
actually present before the transplantation, and all
four AAAs expanded rapidly after the transplanta-
tion. The rapid growth of even small aneurysms may
well be the main reason that there is a high incidence
of clinically apparent AAAs in this population.
Factors that have been proposed to have a role in
this rapid expansion include the significant hemody-
namic alterations after cardiac transplantation associ-
ated with improved cardiac function and the effects
of cyclosporine and prednisone therapy.
To date there have been no AAAs described in
patients after lung transplantation. The number of
lung transplantations performed each year is much
lower than the number of kidney or heart transplan-
tations. As of 1994, there had been over 2700 lung
transplantations performed worldwide with 1- and
3-year survival rates of 70% and 56%, respectively.8
There are thus many fewer survivors of lung trans-
plantations than of the other solid organ transplan-
tations. Also, the indications for lung transplantation
are quite different, with primary pulmonary hyper-
tension, chronic obstructive pulmonary disease,
Eisenmengers syndrome, and cystic fibrosis being
the major indications. One might expect a lower
incidence of underlying atherosclerotic disease in
this population, because they are younger than the
heart transplant recipients.
The AAA developed in our patient at a very early
age, and in 18 months it had expanded at a rate of
0.7 cm/yr. The behavior of his AAA was as seen in
the cardiac transplant population, and this occurred
in the absence of markedly improved hemodynamics
(his ejection fraction was 25%). It is also of interest to
note that our patient’s aneurysm expanded rapidly
although he was undergoing metoprolol therapy.
Recent studies indicate that the effect of beta-block-
ers may be to slow the growth rate of AAAs.9 It
could be that our patient’s long-term use of pred-
nisone, cyclosporine, and azathioprine was an impor-
tant factor in the development and expansion of the
AAA, as it is in the cardiac transplant population.
Given the age of our patient and the fact that two
aneurysms had developed, the possibility of connec-
tive tissue disease cannot be eliminated. Cystic fibro-
sis is not known to affect the vascular system nor is it
known to be associated with connective tissue dis-
ease. In theory, the enzymatic defect involved in this
disease should not affect large arteries.
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Fig 2. A 2.1-cm splenic artery aneurysm in the proximal portion of the artery.
Studies in animal models have shown that pred-
nisone can have a proaneurysmal effect and even induce
rupture in a rat model of aortic aneurysm.10 There is cir-
cumstantial evidence linking long-term use of pred-
nisone with the development of atherosclerosis.11
Aneurysm disease seems to be more common and devel-
ops at an earlier age in patients receiving chronic steroid
therapy for autoimmune diseases.12 Cyclosporine is not
known to induce aneurysmal disease. Research investi-
gating the possible role of cyclosporine in accelerated
graft atherosclerosis has shown that, in animal models,
cyclosporine can have a directly atherogenic effect on
injured vessels.13 Prednisone and cyclosporine can cause
patients to be hypertensive and in this way conceivably
can predispose a patient to vascular disease and
aneurysms.2 The experimental evidence is far from con-
clusive. Based on the supposition that the inflammatory
infiltrate seen in AAAs may be the cause of enlargement
and rupture, Dobrin et al14 reported that the adminis-
tration of cyclosporine and prednisone actually inhibited
the development of aneurysms and aortic enlargement
in a specific animal model. The clinical experience thus
far with patients who have undergone transplantation
and are receiving prednisone and cyclosporine therapy
seems to contradict this observation.
In conclusion, our patient is the first patient with
described AAA after a lung transplantation. His con-
dition and the rapid growth of the aneurysm is similar
to that seen in patients after cardiac transplantation.
This leads us to speculate that the similar immunosup-
pressive regimes are important etiologic agents. It may
be that aneurysms in the lung transplant population
will behave as do those aneurysms in the cardiac trans-
plant group. If this is the case, these aneurysms should
be aggressively managed. It has even been advocated
that all aneurysms in patients who have undergone a
cardiac transplantation be repaired, regardless of size.
Based on this case and the reported experiences of
other authors with heart transplant recipients, we feel
that, if one elects not to immediately repair an abdom-
inal aneurysm in any transplanted patient, serial fol-
low-up of the aneurysm should be performed more
frequently than for the aneurysm population at large.
The aneurysms should be repaired expeditiously if any
abnormally rapid growth is noted. As the number of
survivors of all types of transplantations increases,
more data may become available on the impact of
aneurysmal disease in these patients, and hopefully we
can develop a clearer understanding of the exact role
of steroids and immunosuppression in the develop-
ment and expansion of AAAs.
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